Kato Pharmaceuticals
Laguna Hills, US · Delaware corporation
Founders & leadership
TS
Terrance S. McGovernNamed on SEC filing
MB
Mauro BoveNamed on SEC filing
OB
Olav B. BergheinNamed on SEC filing
HN
Hugh NeuharthNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$8M disclosed across 1 round · 2018
▶$8MraisedOct 2018 · 9 investors · PharmaceuticalsRule 506(b)
▶$8MraisedOct 2018 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Terrance S. McGovernExecutive Officer, Director
- Mauro BoveDirector
- Olav B. BergheinDirector
- Hugh NeuharthExecutive Officer
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Kato Pharmaceuticals raised?
- Kato Pharmaceuticals has disclosed $8M raised across 1 round.
- Where is Kato Pharmaceuticals headquartered?
- Kato Pharmaceuticals is headquartered in Laguna Hills, US.